Journal of Clinical Oncology, Vol 14, 2316-2321, Copyright © 1996 by American Society of Clinical Oncology
Phase II study of paclitaxel in patients with recurrent malignant glioma
MD Prados, SC Schold, AM Spence, MS Berger, LD McAllister, MP Mehta, MR Gilbert, D Fulton, J Kuhn, K Lamborn, DJ Rector and SM Chang
PURPOSE: To assess the efficacy and toxicity of paclitaxel administered as
a 3-hour infusion to patients with recurrent malignant glioma. PATIENTS AND
METHODS: Adult patients with recurrent malignant glioma following radiation
therapy, who had received no more than one prior chemotherapy regimen and
who had a Karnofsky performance status (KPS) > or = 60, were treated
with a 3-hour infusion of paclitaxel every 3 weeks. The initial dose was
210 mg/m2; dose escalation to 240 mg/m2 was allowed. Tumor response was
assessed at 6-week intervals using radiographic and clinical criteria.
Treatment was continued until documented tumor progression or a total of 12
paclitaxel infusions. RESULTS: Of 41 eligible patients, all were assessable
for treatment toxicity and 40 (98%) were assessable for response. The
response rate (disease stabilization or better) was 35%. Twenty-nine
patients (71%) underwent dose escalation to 240 mg/m2 without the use of
growth factors. Toxicities included alopecia (98%), nausea (22%),
arthralgias (32%), CNS toxicity (24%), peripheral neuropathy (15%), cardiac
toxicity (7%), and myelosuppression (10% grade 3 or 4 hematologic
toxicity). No patient developed febrile neutropenia. There was one allergic
reaction (2%). CONCLUSION: Paclitaxel is well tolerated at this dose
schedule in patients with recurrent malignant glioma, and affords a modest
response rate. Because minimal myelotoxicity was encountered in our
patients, a dose-escalating phase I/II study of paclitaxel is planned to
determine the maximal-tolerated dose (MTD).
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al.
Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
Neuro-oncol,
August 1, 2008;
10(4):
631 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Fruehauf, H. Brem, S. Brem, A. Sloan, G. Barger, W. Huang, and R. Parker
In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas
Clin. Cancer Res.,
August 1, 2006;
12(15):
4523 - 4532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. See, V. A. Levin, W.-K. A. Yung, K. R. Hess, and M. D. Groves
13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme
Neuro-oncol,
July 1, 2004;
6(3):
253 - 258.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. D. Katsetos, A. Legido, E. Perentes, and S. J. Mork
Class III {beta}-Tubulin Isotype: A Key Cytoskeletal Protein at the Crossroads of Developmental Neurobiology and Tumor Neuropathology
J Child Neurol,
December 1, 2003;
18(12):
851 - 866.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. W. Li, W. Dang, B. M. Tyler, G. Troiano, T. Tihan, H. Brem, and K. A. Walter
Polilactofate Microspheres for Paclitaxel Delivery to Central Nervous System Malignancies
Clin. Cancer Res.,
August 1, 2003;
9(9):
3441 - 3447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Kemper, A. E. van Zandbergen, C. Cleypool, H. A. Mos, W. Boogerd, J. H. Beijnen, and O. van Tellingen
Increased Penetration of Paclitaxel into the Brain by Inhibition of P-Glycoprotein
Clin. Cancer Res.,
July 1, 2003;
9(7):
2849 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Clarke, R. L. Basser, C. Underhill, P. Mitchell, J. Bartlett, L. Cher, M. Findlay, D. Dalley, M. Pell, M. Byrne, et al.
KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma
J. Clin. Oncol.,
August 1, 1999;
17(8):
2579 - 2579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Tseng, M. S. Bobola, M. S. Berger, and J. R. Silber
Characterization of paclitaxel (Taxol(R)) sensitivity in human glioma- and medulloblastoma-derived cell lines
Neuro-oncol,
April 1, 1999;
1(2):
101 - 108.
[Abstract]
[PDF]
|
|
|
|
